Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416583 | 0.90 | NPC1 (0.54) | SMN1; SMN2KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL7016812 | 0.82 | TP53 (0.46) | SMN1; SMN2KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL4391482 | 0.78 | MAPK1 (0.70) | SMN1; SMN2KMT2ANPSR1ALDH1A1KDM4E | |
| SCHEMBL2566270 | 0.76 | ALDH1A1 (0.51) | SMN1; SMN2KMT2ANPSR1ALDH1A1KDM4E | |
| SCHEMBL4394311 | 0.76 | PDE10A (0.63) | SMN1; SMN2KMT2ANPSR1ALDH1A1KDM4E | |
| SCHEMBL6281164 | 0.75 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2ANPSR1ALDH1A1KDM4E | |
| SCHEMBL3424745 | 0.75 | PDE10A (0.62) | SMN1; SMN2KMT2ANPSR1ALDH1A1KDM4E | |
| SCHEMBL1101909 | 0.75 | LMNA (0.72) | SMN1; SMN2KMT2ANPSR1ALDH1A1KDM4E | |
| SCHEMBL7762374 | 0.75 | PDE7A (0.58) | SMN1; SMN2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL7018385 | 0.74 | TP53 (0.46) | SMN1; SMN2KMT2AALDH1A1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | claimed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | TP53, BRDT, VHL | SMN1; SMN2 155/4885KMT2A 3189/4885NPSR1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.